A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)

Sponsor
AstraZeneca
Study ID
NCT06606847
Phase
PHASE2
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Oleclumab — DRUG
    Oleclumab IV (intravenous infusion)
  • Durvalumab — DRUG
    Durvalumab IV (intravenous infusion)

Study Details

The purpose of this Phase II, open-label, multicentre, single-arm study is to assess efficacy and safety of durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) in participants with locally advanced (Stage III), unresectable non-small cell lung cancer (NSCLC), who have not progressed following platinum-based concurrent or sequential chemoradiotherapy (cCRT or sCRT).

Key Dates

Start date
Sep 24, 2024
Status verified
May 2026
Primary completion
May 4, 2026
Completion
Mar 30, 2027

Study Design

Enrollment
30 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Arm 1
    durvalumab plus oleclumab as an IV infusions

Primary Outcome Measure

Progression free survival (PFS) at 12 months [ Time Frame: From date of first dose until 12 months ]

Related Studies